The United States can expect to see a total of 240 million doses of Covid-19 vaccine by the end of March, according to prepared remarks drug companies will deliver to a House subcommittee today. The vaccine makers are set to testify at 10:30 a.m. ET.
Pfizer and Moderna – the two companies with Covid-19 vaccines authorized for emergency use in the United States – have pledged to make a combined total of 220 million doses available for shipment by the end of March.
Meanwhile, the company Johnson & Johnson, which has yet to receive an emergency use authorization for its Covid-19 vaccine, has pledged to make 20 million doses available in the same time frame.
Each of the vaccine makers, along with the companies AstraZeneca and Novavax, provided prepared remarks ahead of a hearing before the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations on Tuesday. In the remarks, each company detailed the number of doses it plans to provide and when.
Pfizer noted in its remarks that it expects to increase the number of doses available for shipment from about 4 to 5 million doses per week at the beginning of February to more than 13 million doses per week by the middle of March.
"We are on track to make 120 million doses available for shipment by the end of March and an additional 80 million doses by the end of May. And, we anticipate all 300 million contracted doses will be made available for shipment by the end of July, enabling the vaccination of up to 150 million Americans," the company said in its remarks.
Moderna, the other company with an authorized Covid-19 vaccine, noted in its remarks that it is on track to meet a commitment to deliver 100 million doses by the end of March and it plans to double monthly deliveries by April to more than 40 million doses per month.
"Based on this progress scaling up manufacturing, we recently agreed to move up our delivery timeline: we now are aiming to deliver a second hundred million doses by the end of May and a third hundred million doses by the end of July," the company said in its remarks.
Johnson & Johnson, whose vaccine is administered as a single dose, pledged in its remarks to deliver enough single-doses by the end of March to enable the vaccination of more than 20 million Americans, should its vaccine be authorized for emergency use.
Novavax said that it is prepared to deliver 110 million doses, which is included in its current agreements with the US government, by the third quarter of this year. AstraZeneca has noted that it has two agreements with the US government for 300 million doses.